Potential Future Approaches to Neoadjuvant and Adjuvant Immunotherapy for MIBC

A recap of the FDA submissions and regulatory decisions in urology from June 2025.

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

The primary end point for the trial is the complete response rate at 3 months.

“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.

Detalimogene is currently under evaluation in the pivotal phase 1/2 LEGEND trial.

Anne K. Schuckman, MD, describes the growing number of options in NMIBC and the impact of these therapies on clinical practice.